✦ LIBER ✦

OL-047 Long-term therapy with adefovir dipivoxil for HBeAg positive chronic hepatitis B: results from 144 weeks adefovir dipivoxil treatment

✍ Scribed by J. You; L. Zhuang; H.Y. Chen; X. Feng; L. Kong; H. Lei; Y.L. Ma; Y.L. Li; W.B. Yang; J.H. Huang; S.M. Yan; Y.H. Che; Q.Q. Wang; L. Chen

Book ID: 118617764
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 48 KB
Volume: 15
Category: Article
ISSN: 1201-9712
DOI: 10.1016/s1201-9712(11)60108-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.111 Long term therapy with adefovir di

P.111 Long term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B

✍ B. Bhushan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Lamivudine compared with lamivudine and

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B

✍ Joseph J.Y. Sung; Jak-Yiu Lai; Stefan Zeuzem; Wan Chen Chow; E. Jenny Heathcote; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Efficacy of 96 weeks adefovir dipivoxil

Efficacy of 96 weeks adefovir dipivoxil treatment in HBeAg positive chronic hepatitis B patients with various baseline biochemical levels

✍ L. Zhuang; J. You; L. Kong; H. Lei; R.-D. Yang; X. Zhang; Q.-Q. Wang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 84 KB

57 Long-term incidence of adefovir dipiv

57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy

✍ X. Qi; A. Snow; V. Thibault; Y. Zhu; M. Curtis; S.J. Hadziyannis; C.L. Brosgart; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Long-term efficacy and safety of adefovi

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B

✍ Patrick Marcellin; Ting-Tsung Chang; Seng G. Lee Lim; William Sievert; Myron Ton 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 1 views

Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo. The long-term efficacy and safety of AD

P.102 Long-term adefovir dipivoxil treat

P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy

✍ S.J. Hadziyannis; N.C. Tassopoulos; T. Chang; J. Heathcote; G. Kitis; M. Rizzett 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 138 KB